An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- procedure : high dose chemotherapy and autologous hematopoietic cell transplant
Phase: Phase 2
Ages Eligible For Study:
- active chronic GvHD - ANC > 1000/mm^3 - therapeutic cyclosporine